Eye injury

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
Wednesday, April 10, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

TVM Capital Life Science to Participate in LSI USA ’24 Emerging Medtech Summit 2024

Retrieved on: 
Wednesday, March 13, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, Medtech, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • MUNICH, Germany and MONTREAL, March 13, 2024 (GLOBE NEWSWIRE) -- TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • “Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

Retrieved on: 
Monday, April 1, 2024
Glaucoma, Agonist, Rheumatoid arthritis, Phenylephrine, Diabetes, Inflammation, Patient, Ageing, American Optometric Association, Eye injury, American Academy, Mydriasis, United, Viatris, Eye, Parasympatholytic, Uveitis, Lens, Pupil, Tropicamide, FDA, Cataract, Diabetic retinopathy, Food, Pharmaceutical industry

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.

Key Points: 
  • PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States.
  • The onset of action of RYZUMVI generally occurs in 30 minutes.
  • In the MIRA-2 trials' placebo group, 34% of patients were still dilated (had not returned to ≤ 0.2 mm of baseline pupil diameter) at 24 hours.
  • To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.

Prevent Blindness Declares March as Workplace Eye Wellness Month to Encourage Eye Safety Practices, Eye Protection at Work

Retrieved on: 
Wednesday, February 28, 2024
Computer, Social media, Workplace safety, Eye, American National Standards Institute, Visual impairment, Safety, Eye injury, Blue Light, Glare, Headache, GLARE, ANSI, Employment, Tablet, International, American Academy, Personal protective equipment

CHICAGO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading eye health and safety nonprofit organization, has once again declared March as Workplace Eye Wellness Month to encourage employers and employees to make eye safety and eye protection a priority on the job. Prevent Blindness offers a variety of free resources including workplace eye safety fact sheets, shareable social media graphics in English and Spanish, and, to help employers educate workers on eye protection and safety, Prevent Blindness offers the Workplace Safety module in the Healthy Eyes Educational Series.

Key Points: 
  • Prevent Blindness Provides Free Resources on Eye Safety, Blue Light and Digital Eye Strain, and More, to Encourage Employers and Employees to Protect Eyes at Work
    CHICAGO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading eye health and safety nonprofit organization, has once again declared March as Workplace Eye Wellness Month to encourage employers and employees to make eye safety and eye protection a priority on the job.
  • Prevent Blindness offers a variety of free resources including workplace eye safety fact sheets , shareable social media graphics in English and Spanish, and, to help employers educate workers on eye protection and safety, Prevent Blindness offers the Workplace Safety module in the Healthy Eyes Educational Series .
  • Contact with objects or equipment led to the majority of eye injuries and illnesses requiring days away from work in 2020.
  • In the event of any eye injury, Prevent Blindness offers the " First Aid for Eye Emergencies " resource.

Bausch + Lomb Completes Acquisition of XIIDRA®

Retrieved on: 
Friday, September 29, 2023
Science, Research, Pharmaceutical, Optical, General Health, Health, Clinical Trials, Other Health, Taste, Contact, DED, Human, Note, Eye, Inflammation, Bausch & Lomb, Telecanthus, Acquisition, Allergy, Novartis, Patient, Ophthalmology, Eye injury, System, United, FDA, NYSE, Pharmaceutical industry, Telescopic sight, Dietary supplement, Birth control

“We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb.

Key Points: 
  • “We expect to quickly take a leading position in the growing prescription dry eye category with the XIIDRA acquisition and MIEBO launch and, importantly, help the millions of patients not currently receiving adequate treatment for dry eye disease,” said Brent Saunders, chairman and CEO, Bausch + Lomb.
  • Bausch + Lomb also brought on the sales force supporting XIIDRA.
  • The issuance of the Notes and the closing of the Term Loan Facility occurred substantially concurrently with the closing of the acquisition.
  • XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription eye drop used to treat the signs and symptoms of dry eye disease.

New Data from Prevent Blindness Shows More than 32,000 Sports-related Eye Injuries were Treated Last Year, an almost 20 Percent Increase Over the Previous Year

Retrieved on: 
Tuesday, August 29, 2023
Sport, Education, Visual impairment, Blunt trauma, Research to Prevent Blindness, OD, Skiing, Eye, USC, Snow, Parent, Athlete, Social media, Risk, National Eye Institute, Child, Water, Abrasion, Eye injury, Paratriathlon, Injury, Personal protective equipment, Telescopic sight, Tutoring, Optometry

CHICAGO, Aug. 29, 2023 /PRNewswire-PRWeb/ -- New annual data from Prevent Blindness, the nation's leading eye health nonprofit organization, shows that there were more than 32,000 sports-related eye injuries treated in the United States last year, an increase of almost 20 percent from the previous year. To educate the public on the risk of significant and potentially blinding eye injuries and the need for proper eye protection, Prevent Blindness has declared September as Sports Eye Safety Month.

Key Points: 
  • To educate the public on the risk of significant and potentially blinding eye injuries and the need for proper eye protection, Prevent Blindness has declared September as Sports Eye Safety Month.
  • "A sports-related eye injury can happen in an instant, but the effects may last a lifetime," said Jeff Todd, president and CEO of Prevent Blindness.
  • The new Prevent Blindness data showed once again that the category of "non-powder guns, darts, arrows, and slingshots" had the overall highest rate of eye injuries.
  • Types of sports-related eye injuries include blunt trauma, penetrating injuries, eye infections, and corneal scratches and abrasions.

RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update

Retrieved on: 
Wednesday, August 2, 2023
Blood pressure, Glaucoma, Blepharoplasty, Ptosis, Orthostatic hypotension, Hypotension, Conference call, Focal neurologic signs, Stroke, Cardiovascular disease, Eye, Orbit, Myasthenia gravis, Beta blocker, Hypertension, Telecanthus, Ophthalmoparesis, Metabolism, Patient, Xanthine oxidase inhibitor, Risk, Eye injury, Glycosidic bond, System, Aneurysm, Headache, Conference, Horner's syndrome, Phosphorus, Pharmaceutical industry

UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.

Key Points: 
  • UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is indicated for the treatment of acquired blepharoptosis in adults.
  • Ptosis may be associated with neurologic or orbital diseases such as stroke and/or cerebral aneurysm, Horner syndrome, myasthenia gravis, external ophthalmoplegia, orbital infection and orbital masses.
  • Consideration should be given to these conditions in the presence of ptosis with decreased levator muscle function and/or other neurologic signs.
  • Caution is advised in patients taking monoamine oxidase inhibitors which can affect the metabolism and uptake of circulating amines.

Bausch + Lomb Will Acquire XIIDRA®

Retrieved on: 
Friday, June 30, 2023
Health, FDA, Medical Devices, General Health, Pharmaceutical, Optical, Biotechnology, Taste, Contact, Wardwell, DED, Human, Wachtell, Lipton, Rosen & Katz, Prevalence, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, Research, Inflammation, Element, Bausch & Lomb, Telecanthus, Acquisition, Allergy, Patient, Davis Polk, Eye injury, System, NYSE, J. P. Morgan, Pharmaceutical industry, Telescopic sight, Dietary supplement, Birth control, Novartis

Bausch + Lomb will also bring on the sales force supporting XIIDRA.

Key Points: 
  • Bausch + Lomb will also bring on the sales force supporting XIIDRA.
  • Bausch + Lomb has obtained fully committed financing from J.P. Morgan for the transaction and intends to finance the $1.75 billion upfront cash purchase price with new debt prior to closing.
  • Bausch + Lomb intends to maintain its strong balance sheet and expects to return to current leverage levels within approximately 24 months of closing.
  • J.P. Morgan served as financial advisor to Bausch + Lomb.

Globus Group partners with Asda to provide high-performance safety eyewear for industry

Retrieved on: 
Thursday, June 1, 2023
ASDA, Partnership, Globus (company), RX, Asda, PPE, Eye injury, Dust, Safety, Pharmaceutical industry, Cryptocurrency, Personal protective equipment, EU

The state-of-the-art Riley and ASDA prescription eyewear service allows prescription protection eyewear to be ordered in a simple three-step process.

Key Points: 
  • The state-of-the-art Riley and ASDA prescription eyewear service allows prescription protection eyewear to be ordered in a simple three-step process.
  • Alex Parker, Managing Director at Vision Lab, said: "We are pleased to partner with Asda to provide high-quality Riley® RX prescription safety eyewear to customers across the UK."
  • Engineered using the latest safety eyewear technology, innovative designs, and unique performance features, Riley RX prescription safety lenses are suited to a wide range of applications.
  • Stephen Platt, Product Sales Specialist, said: The Riley partnership with Asda Opticians further enhances our market leading prescription safety eyewear offer.